Low-dose aspirin fails to cut prostate cancer mortality in Danish study

  • Skriver C & al.
  • Ann Intern Med
  • 5 Mar 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Postdiagnosis low-dose aspirin use in patients with prostate cancer was not associated with lower overall risk for prostate cancer mortality.
  • In secondary analysis, low-dose aspirin use was inversely associated with prostate cancer mortality at 5 and 7.5 years postdiagnosis.

Why this matters

  • Recent studies suggest a survival benefit with aspirin use in patients with prostate cancer, but study results are inconclusive.

Study design

  • 29,136 patients with prostate cancer who received low-dose aspirin postdiagnosis (dose, 75-150 mg; ≥2 prescriptions filled within 1 year).
  • Funding: Danish Cancer Society.

Key results

  • 7633 prostate cancer-related deaths were reported during a median follow-up of 4.9 years.
  • 24.6% of patients used low-dose aspirin.
  • Postdiagnosis low-dose aspirin use was not associated with overall prostate cancer-specific mortality (aHR, 0.95; 95% CI, 0.89-1.01).
  • In secondary analysis of extended exposure periods, postdiagnosis low-dose aspirin use was associated with reduction in risk for prostate cancer mortality at 5 years (aHR, 0.91; 95% CI, 0.83-1.01) and 7.5 years (aHR, 0.84; 95% CI, 0.72-0.97).

Limitations

  • Over-the-counter aspirin use was not known.